Mark T. Fleming - Concepedia

Author

Mark T. Fleming

Also Known As

Ali El-Ghorr, Edward McClay, M Fleming, M. Fleming, M. T. Fleming, M.T. Fleming, Mark Fleming, Mark T Fleming, Mark T. Fleming

213

Publications

15.6K

Citations

H-Index

134

Concepts

All Affiliations

Virginia Oncology Associates Institut Gustave Roussy University of Washington Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center

About

Mark T. Fleming is an author at Virginia Oncology Associates specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	7	7	508
2	Health Sciences	6	6	285
3	Business	4	4	367
4	Education	1	1	35
5	Law	1	1	27

Mark T. Fleming

Publications

14.9K

Citations

H-Index

Page 1

	Year	Citations
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim Fizazi, Fred Saad, New England Journal of Medicine	2012	4.5K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Yohann Loriot, Andrea Necchi, Se Hoon Park, New England Journal of Medicine	2019	1.3K
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Measuring safety climate on offshore installations Kathryn Mearns, Rhona Flin, Rachale Gordon, Work & Stress	1998	299
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyCancer Treatment	2021	269
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Human and organizational factors in offshore safety Kathryn Mearns, Rhona Flin, Rachael Gordon, Work & Stress EngineeringMarine SafetySafety ScienceInjury PreventionHuman Resource Management	2001	221
Identifying, understanding and overcoming barriers to medication error reporting in hospitals: a focus group study Nicole R. Hartnell, Neil J. MacKinnon, Ingrid Sketris, BMJ Quality & Safety	2012	180
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, The Lancet Oncology UrologyOncologyMetastatic Urothelial CarcinomaGenitourinary CancerCancer Management	2022	162

Page 1